Answers are grounded in this paper and cite their sources.
OBJECTIVE: To assess and compare the incidences of herpes zoster (HZ) in rheumatoid arthritis patients (RA) receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), in b/tsDMARD-naïve RA, and general population. METHODS: We identified all patients with RA in Sweden 2014-2024, and b/tsDMARD starts among them, through register linkages. For each b/ts-DMARD treatment start, five age/sex-matched population controls were selected. A history of HZ was defined as a listing with an ICD-10 code for HZ and/or dispensation of an antiviral drug up to one year before treatment start. Incident HZ was defined as the first HZ ICD-10 code during follow-up accompanied by prescription of an antiviral within 90 days. RESULTS: 77694 unique RA patients contributed to the following: 69962 subjects in the b/tsDMARD-naïve cohort, and 20033 TNFi-, 9410 non-TNFi-, and 4023 JAKi-treatment episodes. Based on 95 incident HZ cases (incidence rate (IR) 2.0, 95% confidence interval 1.6-2.4 per1000 person-years) with TNFi, 55 cases (IR 2.4, 95% CI 1.8-3.1) with non-TNFi, 41 cases (IR 5.1, 95% CI 3.7-6.9) with JAKi, 561 cases (IR 1.5, 95% CI 1.4-1.6) in b/tsDMARD-naive RA and 494 cases (IR 0.6, 95% CI 0.6-0.7) in the general population, the multivariable-adjusted hazard ratio (using TNFi as reference) with JAKi was HR = 1.9; 95% CI 1.2-3.0 and HR = 0.9; 95% CI 0.6-1.3 for non-TNFi. CONCLUSION: The incidence of a first ever HZ is higher in b/tsDMARD-naïve patients compared to general population, is further and similarly increased in patients receiving TNFi or non-TNFi, and yet higher in those starting JAKi.
No takes yet. Share an insight, caveat, or question.
Kapetanovic et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: